Funding for this research was provided by:
Bundesministerium für Wirtschaft und Energie (KF2664503CS1)
Received: 21 April 2021
Accepted: 22 July 2021
First Online: 3 September 2021
: FB, MB, DB, GS, MR, BK, MK, DH, CGZ, ASM, AL, AC, OS, GS, MP, TF have no conflict of interest; LP and ML are employees of MEDIAGNOST, Reutlingen, Germany which developed and markets the progranulin assay used in the study, and hold a patent on progranulin together with IK. JNB, NMA, JCP are employees of Qiagen Digital Insights, which markets the <i>Ingenuity Pathway Analysis</i> software package used for data analysis in the study.
: For studying the exploratory cohort, written approval was obtained from the Ethics Committee of the Friedrich-Schiller-University of Jena, Germany (Protocol# 2242-03/08, EudoraCT# 2006-006984-21, trial registration number NCT00832039) in cooperation with the local Ethics Committee of the Ludwig-Maximilians-University of Munich, Germany (amendment 13.01.2010). The confirmatory study was approved by the Ethics Committee of the Medical Faculty of the University of Munich under a separate protocol (protocol #551-14, trial registration number NCT03280576). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent for publication of blinded personal data was obtained from each participant or the patient’s legal representative.
: All study participants gave informed consent for publishing blinded personal data and the use of materials obtained during the study for laboratory analysis.